Safety and tolerability of ceftobiprole

Mostra el registre complet Registre parcial de l'ítem

  • dc.contributor.author Grau Cerrato, Santiago
  • dc.date.accessioned 2020-04-14T07:12:42Z
  • dc.date.available 2020-04-14T07:12:42Z
  • dc.date.issued 2019
  • dc.description.abstract Ceftobiprole is a fifth generation cephalosporin with a series of characteristics differentiating it from other beta-lactams, including its antibacterial activity, mainly against methicillin-resistant Staphylococcus aureus, resistant Streptococcus pneumoniae and also Gram-negative microorganisms such as Pseudomonas aeruginosa. This antibiotic has been subjected to various clinical trials and the results of these have led to its approval in Spain for the treatment of nosocomial pneumonia, excluding that associated with mechanical ventilation, and community-acquired pneumonia. The results of various ceftobiprole clinical studies provide consistent information on efficacy and tolerability. Ceftobiprole as monotherapy has been shown to be non-inferior to comparator antibiotics in different settings. Information is available on its compatibility with other drugs in Y-site administration, important from the point of view of the intravenous treatment of patients who present venous access limitation. On the other hand, and in contrast to other cephalosporins, ceftobiprole presents a low risk of infection due to Clostridium difficile and, in comparison with ceftaroline, neutropenia has not been reported to present any significant issues.
  • dc.format.mimetype application/pdf
  • dc.identifier.citation Grau S. Safety and tolerability of ceftobiprole. Rev Esp Quimioter. 2019 Sep;32 Suppl 3(Suppl 3):34-6.
  • dc.identifier.issn 0214-3429
  • dc.identifier.uri http://hdl.handle.net/10230/44200
  • dc.language.iso eng
  • dc.publisher Sociedad Española de Quimioterapia
  • dc.relation.ispartof Sociedad Española de Quimioterapia. 2019 Sep;32 Suppl 3(Suppl 3):34-6
  • dc.rights Copyright © The Author 2019. This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0) (https://creativecommons.org/licenses/by-nc/4.0/). https://creativecommons.org/licenses/by-nc/4.0/
  • dc.rights.accessRights info:eu-repo/semantics/openAccess
  • dc.rights.uri http://creativecommons.org/licenses/by-nc/4.0/
  • dc.subject.other Ceftobiprole
  • dc.subject.other Medicaments -- Anàlisi
  • dc.title Safety and tolerability of ceftobiprole
  • dc.type info:eu-repo/semantics/article
  • dc.type.version info:eu-repo/semantics/publishedVersion